Drug intelligence / Profile preview

cephalosporins + macrolide

Development stage: Unknown
Lead developer: Macrolide Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination antibiotic therapy consisting of cephalosporins (typically third-generation) and macrolide antibiotics. This combination is recommended by international guidelines for the treatment of moderate to severe community-acquired pneumonia (CAP). The cephalosporin component provides coverage against common bacterial pathogens, while the macrolide covers atypical pathogens and may provide additional anti-inflammatory effects.

Targets

NPET (Bacterial 50S ribosomal subunit – 23S rRNA nascent peptide exit tunnel)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cephalosporins + macrolide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cephalosporins + macrolide.

Explore the full profile